Current Report Filing (8-k)
November 22 2017 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 21, 2017
MARRONE
BIO INNOVATIONS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36030
|
|
20-5137161
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
1540
Drew Avenue, Davis, CA
|
|
95618
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (530) 750-2800
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
5.08 Shareholder Director Nominations.
(a)
To the extent applicable, the information in Item 8.01 of this Form 8-K is incorporated by reference into this Item 5.08.
Item
8.01 Other Events.
On
November 21, 2017, the Board of Directors of Marrone Bio Innovations, Inc. (the “Company”) determined to schedule
the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”) for Wednesday, January 17, 2018. The
time and location of the Annual Meeting will be as set forth in the Company’s definitive proxy statement for the Annual
Meeting to be filed with the Securities and Exchange Commission.
Pursuant
to the Company’s Amended and Restated Bylaws, if a stockholder of the Company intends a proposal to be considered for inclusion
in the Company’s proxy statement for the Annual Meeting, stockholder proposals must be delivered to the principal executive
offices of the Company, at 1540 Drew Ave., Davis, California 95618, Attention: Corporate Secretary, not later than December 3,
2017. Additionally, notice of any stockholder proposal (including a proposal to nominate a candidate for director) that is not
submitted for inclusion in the proxy statement for the Annual Meeting must be delivered to or mailed and received at the principal
executive offices of the Company not later than December 3, 2017. Any stockholder proposal or director nomination must also comply
with the requirements of Delaware law, the rules and regulations promulgated by the SEC and the Company’s Amended and Restated
Bylaws, as applicable. Any notice received after December 3, 2017 will be considered untimely and not properly brought before
the Annual Meeting.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MARRONE
BIO INNOVATIONS, INC.
|
|
Dated:
November 22, 2017
|
By:
|
/s/
Linda V. Moore
|
|
|
Linda
V. Moore
|
|
|
Executive
Vice President, General Counsel and Secretary
|
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Sep 2023 to Sep 2024